APA (7th ed.) Citation

Zugasti, I., Lopez-Guerra, M., Castaño-Díez, S., Esteban, D., Avendaño, A., Pomares, H., . . . Riu, G. (2025). Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: A GESMD study. Experimental Hematology & Oncology, 14(1), 1. https://doi.org/10.1186/s40164-025-00652-5

Chicago Style (17th ed.) Citation

Zugasti, Ines, et al. "Hypomethylating Agents Plus Venetoclax for High-risk MDS and CMML as Bridge Therapy to Transplant: A GESMD Study." Experimental Hematology & Oncology 14, no. 1 (2025): 1. https://doi.org/10.1186/s40164-025-00652-5.

MLA (9th ed.) Citation

Zugasti, Ines, et al. "Hypomethylating Agents Plus Venetoclax for High-risk MDS and CMML as Bridge Therapy to Transplant: A GESMD Study." Experimental Hematology & Oncology, vol. 14, no. 1, 2025, p. 1, https://doi.org/10.1186/s40164-025-00652-5.